The Estée Lauder Companies Partners with Serpin Pharma, Inc to Develop Breakthrough Skin Care Ingredients to Advance Longevity
The Estée Lauder Companies (NYSE: EL) has announced an exclusive partnership with biotechnology company Serpin Pharma to develop innovative skin care ingredients focused on longevity benefits. The collaboration will leverage Serpin Pharma's anti-inflammatory research and proprietary biotech technology based on SERPINs (Serine Protease Inhibitors) to address skin irritation, aging, and sensitivity.
The partnership aims to translate Serpin's technology, which enhances the body's natural healing ability through innate immune response, into cosmetic applications. Scientific studies are currently underway to demonstrate the technology's effectiveness in rapidly reducing visible skin aging and irritation.
This initiative aligns with ELC's Beauty Reimagined strategic vision and builds upon their 75-year history in longevity science, biotechnology, and fermentation. The company maintains R&D and Innovation Centers globally, with scientists specializing in physics, chemistry, biology, and engineering.
Le Estée Lauder Companies (NYSE: EL) hanno annunciato una partnership esclusiva con la compagnia biotecnologica Serpin Pharma per sviluppare ingredienti innovativi per la cura della pelle focalizzati sui benefici per la longevità. La collaborazione sfrutterà la ricerca anti-infiammatoria di Serpin Pharma e la sua tecnologia biotecnologica proprietaria basata sui SERPIN (Inibitori delle Serine Proteasi) per affrontare l'irritazione della pelle, l'invecchiamento e la sensibilità.
La partnership mira a tradurre la tecnologia di Serpin, che migliora la capacità di guarigione naturale del corpo attraverso la risposta immunitaria innata, in applicazioni cosmetiche. Attualmente sono in corso studi scientifici per dimostrare l'efficacia della tecnologia nella riduzione rapida dell'invecchiamento visibile della pelle e dell'irritazione.
Questa iniziativa è in linea con la visione strategica di ELC, Beauty Reimagined, e si basa sulla loro storia di 75 anni nella scienza della longevità, biotecnologia e fermentazione. L'azienda mantiene centri di R&D e innovazione a livello globale, con scienziati specializzati in fisica, chimica, biologia e ingegneria.
Las Empresas Estée Lauder (NYSE: EL) han anunciado una asociación exclusiva con la compañía de biotecnología Serpin Pharma para desarrollar ingredientes innovadores para el cuidado de la piel enfocados en los beneficios de longevidad. La colaboración aprovechará la investigación antiinflamatoria de Serpin Pharma y su tecnología biotecnológica propietaria basada en SERPINs (Inhibidores de Serina Proteasa) para abordar la irritación de la piel, el envejecimiento y la sensibilidad.
La asociación tiene como objetivo traducir la tecnología de Serpin, que mejora la capacidad natural de curación del cuerpo a través de la respuesta inmune innata, en aplicaciones cosméticas. Actualmente se están llevando a cabo estudios científicos para demostrar la efectividad de la tecnología en la reducción rápida del envejecimiento visible de la piel y la irritación.
Esta iniciativa se alinea con la visión estratégica de ELC, Beauty Reimagined, y se basa en su historia de 75 años en la ciencia de la longevidad, biotecnología y fermentación. La empresa mantiene centros de I+D e innovación a nivel mundial, con científicos especializados en física, química, biología e ingeniería.
에스티 로더 컴퍼니즈 (NYSE: EL)는 생명공학 회사 서핀 파마와 장수 이점을 중점으로 둔 혁신적인 피부 관리 성분을 개발하기 위한 독점 파트너십을 발표했습니다. 이 협업은 서핀 파마의 항염증 연구와 SERPIN(세린 프로테아제 억제제)을 기반으로 한 독점 생명공학 기술을 활용하여 피부 자극, 노화 및 민감성을 해결합니다.
파트너십의 목표는 신체의 자연 치유 능력을 선천적인 면역 반응을 통해 향상시키는 서핀의 기술을 화장품 응용 프로그램으로 전환하는 것입니다. 현재 피부의 가시적인 노화 및 자극을 빠르게 줄이는 기술의 효과를 입증하기 위한 과학적 연구가 진행 중입니다.
이 이니셔티브는 ELC의 Beauty Reimagined 전략적 비전과 일치하며, 장수 과학, 생명공학 및 발효 분야에서 75년의 역사를 바탕으로 합니다. 이 회사는 전 세계적으로 R&D 및 혁신 센터를 운영하며, 물리학, 화학, 생물학 및 공학을 전문으로 하는 과학자들이 있습니다.
Les entreprises Estée Lauder (NYSE: EL) ont annoncé un partenariat exclusif avec la société de biotechnologie Serpin Pharma pour développer des ingrédients innovants pour les soins de la peau axés sur les bénéfices de longévité. La collaboration tirera parti de la recherche anti-inflammatoire de Serpin Pharma et de sa technologie biotechnologique propriétaire basée sur les SERPINs (Inhibiteurs de Protéases de Sérine) pour traiter l'irritation de la peau, le vieillissement et la sensibilité.
Le partenariat vise à traduire la technologie de Serpin, qui améliore la capacité naturelle de guérison du corps grâce à la réponse immunitaire innée, en applications cosmétiques. Des études scientifiques sont actuellement en cours pour démontrer l'efficacité de la technologie dans la réduction rapide du vieillissement visible de la peau et de l'irritation.
Cette initiative s'inscrit dans la vision stratégique d'ELC, Beauty Reimagined, et s'appuie sur leur histoire de 75 ans dans la science de la longévité, la biotechnologie et la fermentation. L'entreprise maintient des centres de R&D et d'innovation à l'échelle mondiale, avec des scientifiques spécialisés en physique, chimie, biologie et ingénierie.
Die Estée Lauder Companies (NYSE: EL) haben eine exklusive Partnerschaft mit dem Biotechnologieunternehmen Serpin Pharma angekündigt, um innovative Inhaltsstoffe für die Hautpflege zu entwickeln, die sich auf die Vorteile der Langlebigkeit konzentrieren. Die Zusammenarbeit wird die anti-inflammatorische Forschung von Serpin Pharma und deren proprietäre Biotechnologie, die auf SERPINs (Serin-Protease-Inhibitoren) basiert, nutzen, um Hautirritationen, Alterung und Empfindlichkeit anzugehen.
Das Ziel der Partnerschaft ist es, die Technologie von Serpin, die die natürliche Heilungsfähigkeit des Körpers durch die angeborene Immunantwort verbessert, in kosmetische Anwendungen zu übersetzen. Derzeit laufen wissenschaftliche Studien, um die Wirksamkeit der Technologie bei der schnellen Reduzierung sichtbarer Hautalterung und Irritationen zu demonstrieren.
Diese Initiative steht im Einklang mit der strategischen Vision von ELC, Beauty Reimagined, und baut auf ihrer 75-jährigen Geschichte in der Langlebigkeitsforschung, Biotechnologie und Fermentation auf. Das Unternehmen unterhält weltweit F&E- und Innovationszentren mit Wissenschaftlern, die auf Physik, Chemie, Biologie und Ingenieurwesen spezialisiert sind.
- Exclusive partnership securing innovative anti-inflammatory technology
- Access to proprietary biotech technology with demonstrated efficacy
- Expansion into cutting-edge longevity science applications
- Strategic alignment with fast-to-market innovation goals
- Scientific studies still ongoing - no immediate product launch
- Effectiveness in cosmetic applications yet to be proven
Insights
Estée Lauder Companies' exclusive partnership with Serpin Pharma represents a strategic pivot toward biotechnology-driven innovation at a critical time for the prestige beauty giant. This collaboration taps into Serpin's proprietary anti-inflammatory technology derived from SERPINs (Serine Protease Inhibitors) - proteins that naturally regulate the body's inflammatory response.
This partnership addresses three key market opportunities: First, it targets the rapidly growing "inflammaging" segment, where consumers increasingly understand inflammation's role in skin aging. Second, it positions ELC to compete more effectively against science-forward brands like Estée Lauder-owned Clinique and competitors like L'Oréal's SkinCeuticals that have gained market share. Third, it could yield proprietary ingredients that command premium pricing and margins in an increasingly commoditized beauty market.
The timing is particularly strategic as ELC implements its Beauty Reimagined vision following recent underperformance in key markets like China. By accelerating "fast-to-market" innovation in high-demand categories, ELC aims to revitalize growth across its brand portfolio.
From an execution perspective, ELC brings significant commercialization expertise with its global R&D infrastructure and 75-year formulation history. Meanwhile, Serpin contributes specialized expertise in biomimicry - leveraging natural biological mechanisms rather than synthetic approaches.
For investors, this represents ELC's commitment to differentiation through proprietary science rather than marketing alone - a potential long-term value driver in the increasingly competitive and discerning prestige beauty market.
ELC will step-change innovation by translating innovative anti-inflammation research into cutting-edge skin care solutions
The exclusive partnership will accelerate ELC’s focus on transformative product innovation by applying insights from Serpin Pharma’s two decades of anti-inflammatory research, which has yielded proprietary biotech technology demonstrating remarkable efficacy mitigating harmful inflammation and enhancing cell resiliency. Serpin Pharma identified a key portion of a superfamily of proteins called SERPINs (Serine Protease Inhibitors) that enhance the body’s natural ability to heal cells experiencing inflammation. Together, the companies are investigating how this innovative technology, which leverages the body’s innate immune response, can be harnessed to address skin irritation, aging, and sensitivity. Scientific studies are underway to demonstrate how Serpin’s technology can be applied to cosmetic products to rapidly and visibly reduce skin aging and irritation.
“This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery,” said Carl Haney, Executive Vice President, Global Innovation and Research and Development (R&D), The Estée Lauder Companies. “In partnership with Serpin Pharma, we’re exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide.”
“Serpin Pharma was founded on the principles of biomimicry and how nature solves for signs of trauma and injury,” said Cohava Gelber, PhD, MBA, Founder, Executive Chairperson and CEO, Serpin Pharma. “We’re taking a novel approach by tapping into the body’s innate mechanism for resolving inflammation. We are proud to partner with ELC to explore how our powerful biotechnology can be applied to cosmetics and skin care.”
This work builds on ELC’s decades-long leadership in longevity science, biotechnology and fermentation. The company is step-changing innovation by partnering with biotech companies across sectors to commercialize their breakthrough innovations and applying their cutting-edge technologies to developing skin care solutions for consumers. It also reinforces ELC’s commitment to creating transformative product innovation to deliver fast-to-market, on-trend innovation across in-demand subcategories, benefits, and occasions, as part of ELC’s newly unveiled Beauty Reimagined strategic vision.
With R&D and Innovation Centers around the world, ELC's scientists have multidisciplinary expertise ranging from basic science and advanced technologies to the intersections of physics, chemistry, biology, and engineering. ELC R&D has 75 years of formulation authority and is deeply integrated into the scientific community, regularly presenting at leading events, publishing in peer-reviewed journals, and partnering with leading scientists, institutions, and academia across a broad array of sectors.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN
About Serpin Pharma, Inc
Serpin Pharma is a trailblazing, clinical-stage pharmaceutical company committed to the development of groundbreaking anti-inflammatory and immune-modulating therapies aimed at effectively treating diseases driven by inflammation. Located in
This innovative drug platform by Serpin Pharma not only halts unchecked inflammation without compromising the immune system but also promotes the repair and regeneration of cells and tissues affected by inflammation, injury, or trauma. With thirteen robust patents securing its pipeline technologies, Serpin Pharma stands on the cusp of pioneering breakthroughs that promise to reshape the landscape of therapeutic treatments.
ELC-C
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225925375/en/
Alyssa Kressel
akressel@estee.com
Source: The Estée Lauder Companies Inc.
FAQ
What is the main focus of EL's partnership with Serpin Pharma?
How does Serpin Pharma's technology work in EL's skincare development?
What are the expected benefits of EL's new skincare technology?
How does this partnership align with EL's strategic vision?
